Prostate cancer progression requires active androgen receptor (AR) signaling which occurs following translocation of AR from the cytoplasm to the nucleus. Chemotherapy with taxanes improves survival in patients with castrate resistant prostate cancer (CRPC). Taxanes induce microtubule stabilization, mitotic arrest and apoptotic cell death, but recent data suggest taxanes can also affect AR signaling. Here we report that taxanes inhibit ligand-induced AR nuclear translocation and downstream transcriptional activation of AR target genes such as PSA. AR nuclear translocation was not inhibitied in cells with acquired β-tubulin mutations that prevent taxane-induced microtubule stabilization, confirming a role for microtubules in AR trafficking.
.
INTRODUCTION
Prostate cancer (PC) is the most commonly diagnosed cancer and the second leading cause of cancer-related death in men in the United States. In PC, growth and disease progression requires active androgen receptor (AR) signaling, which occurs following translocation of AR from the cytoplasm to the nucleus where AR, acting as a transcription factor, binds to and activates AR-target genes [1] [2] [3] . Continued AR signaling remains essential to PC progression following androgen withdrawal (castration), with recent data suggesting that intra-tumoral androgen synthesis stimulates PC growth in patients with castrate resistant prostate cancer (CRPC) [4] . Agents that target the AR signaling axis in patients with CRPC have recently demonstrated significant clinical activity in patients with CRPC [5] , corroborating the importance of AR as a therapeutic target in CRPC patients.
Cytotoxic chemotherapy has been used to treat patients with advanced PC for over 20 years [6] . However, the taxanes represent the only class of chemotherapy agents demonstrated to improve survival of patients with metastatic CRPC; docetaxel and recently cabazitaxel are the standard for CRPC treatment [7] [8] [9] . At the cellular level, taxanes bind β-tubulin and stabilize the microtubule cytoskeleton which, in actively dividing cells leads to mitotic arrest and apoptotic cell death [10] . However, in contrast to cancer cells cultured in vitro, cancer cells in patients often display very slow doubling times [11, 12] , suggesting that the clinical activity of taxanes cannot be attributed solely to their antimitotic effects and that it is important to understand the functional consequences of taxane-induced microtubule stabilization in cells during interphase [13] . Accordingly, we have previously shown that dynamic interphase microtubules regulate the intracellular transport and activity of two other transcription factors, p53 and HIF-1α [14] [15] [16] [17] . A number of recent reports by us and others suggest that taxane chemotherapy can inhibit AR signaling in PC cells [18] [19] [20] . Here, we define the mechanisms of taxane inhibition of AR and .
propose AR localization in PC circulating tumor cells (CTCs) as a predictor of response/resistance to taxane chemotherapy in patients with CRPC.
MATERIALS AND METHODS

Cell culture and antibodies
The prostate cancer cell lines LNCaP, PC3 and PC3/AR were derived and maintained as previously described [21] [22] [23] . The PC3/mCherry-tubulin cell line was generated in our laboratory by stably transfecting PC3 prostate cancer cells with pcDNA3:mCherry-tubulin plasmid which was a generous gift from the laboratory of Dr. Tsien (UCSD, CA) and selecting transfected cells with 200 μg/ml neomycin (G418). The following antibodies were used for immunofluorescence staining and western blotting: rabbit polyclonal anti-AR (N-20) and goat polyclonal anti-PSA (C-19) from Santa Cruz Biotechnology, Inc (Santa Cruz, CA), mouse monoclonal anti-prostatespecific membrane antigen (PSMA) J591 [24, 25] , rat monoclonal anti α-tubulin was from Novus Biologicals (Littleton, CO), mouse monoclonal anti-c-myc was from Oncogene Research Products (Darmstadt, Germany), mouse monoclonal antibody against dynein intermediate chain (IC74) was from Covance (Emeryville, CA). All the Alexa conjugated secondary antibodies were from Molecular probes (Eugene, OR). NLP-005 Methyltrienolone (R1881) was purchased from Perkin Elmer (Boston, MA). Paclitaxel and docetaxel were from Sigma.
Determination of secreted PSA levels
LNCaP cells were cultured on 6 well plates and treated overnight with either docetaxel at the indicated concentrations or the di-hydroxytestosterone (DHT) analog, R1881, at 10 nM for 1 hr or the combination of R1881 treatment following incubation with docetaxel. Supernatant were diluted 1:10 with Abbott Laboratories Free and Total PSA Specimen Diluent. Secreted PSA level . measurements were made on Abbott Diagnostics IMx MEIA system (Abbott Park, IL) as previously described [18] .
Measurement of PSA-luciferase activity
LNCaP cells were transiently co-transfected with a dual-luciferase reporter assay system in which luciferase is under the control of a promoter containing androgen-responsive elements (ARE-Luciferase) from the prostate-specific antigen (PSA) gene (Promega Corp., Madison, WI)
[26] and pRL-TK-luc, Renilla luciferase reporter construct (kindly provided by P. Vertino, Emory University, Atlanta, GA), upon reaching 60% confluency on 6 well plates. Thirty hours post-transfection cells were incubated overnight with either DMSO (vehicle control) or taxanes (paclitaxel or docetaxel) at the indicated concentrations followed by 1 hr treatment with R1881 at either 1nM or 10nM concentration. Cells were harvested and cell lysates were prepared for luciferase assays. Each transfection experiment was performed in triplicate. Results represent an average of at least three independent biological repeats with data presented as relative PSA luciferase activity normalized to Renilla luciferase values.
Establishment of 1A9 cancer cell lines overexpressing AR
The parental ovarian cancer cells 1A9 and their derived beta-tubulin mutant, paclitaxelinsensitive clone PTX10 [27] were transfected with a pFLAG-hAR plasmid using lipofectamine (Invitrogen) following the manufacturer's instructions. Cells were selected using G418 (300 ug/ml) and AR-expressing clones (as verified by Western Blot analysis) were named 1A9/AR and PTX10/AR cells, respectively. To evaluate AR trafficking to the nucleus, 1A9/AR and PTX10/AR cells were plated on Cell-tak-coated coverslips in RPMI 1640 containing 10% FCS and switched to medium containing 10% charcoal stripped serum (CS) for 72 hours. Following treatments without (control) or with 1) DHT (100 nM) for 2 hours; or 2) PTX (100 nM) for 2 hrs, followed by DHT (100 nM) for 2 hours, cells were fixed with PHEMO buffer [16] and . immunostained using antibodies against AR (PG21, Millipore, 1:200) and alpha tubulin (1:1000) followed by Alexa 647 (1:1000) and Alexa 568 (1:500) secondary antibodies and DAPI staining.
Western blotting and immunoprecipitation
Control untreated and treated cells were lysed in TNES buffer containing 50 mM Tris (pH 7.5) 100 mM NaCl, 2 mM EDTA, 1% Nonidet P-40, and a 1X protease inhibitor mixture (Roche Applied Science). For the immunoprecipitation experiments, 0.5 mg of soluble cell extract was immunoprecipitated with either a rat α-tubulin or a mouse antibody directed against dynein intermediate chain (IC74) and their respective IgG controls, using protein-G plus agarose (Calbiochem, Darmstadt, Germany) as recommended by the manufacturer. Immunoprecipitated proteins and 50 μg of total cell extracts were resolved by 10% SDS-PAGE and immunoblotted for the indicated proteins. Immunoblots were analyzed with the Odyssey infrared imaging system (LI-COR, Lincoln, NE).
Dynamitin overexpression
For the dynamitin overexpression experiments, LNCaP and PC3-AR cells were plated on 12mm glass coverslips (Electron Microscopy Sciences, Hatfield, PA) and transiently transfected with cmyc-tagged pCMVH50m plasmid containing dynamitin, a kind gift from R. Vallee (Columbia University, New York, NY) [28] . All transfections were performed using FuGENE 6 transfection reagent (Roche Applied Science, Indiananpolis, IN) according to the manufacturer's recommendations. C-myc-dynamitin transfected cells were processed for immunofluorescence labeling using the following primary antibodies: anti-AR rabbit polyclonal and an anti-c-Myc mouse monoclonal. The secondary antibodies used were Alexa 488-conjugated goat anti-rabbit immunoglobulin G (IgG; 1:500) and Alexa 568-conjugated goat anti-mouse IgG (1:500). Cells were then analyzed by confocal microscopy. captured CTCs were cytospun onto Cell-Tak-(BD Biosciences, San Jose, CA) -coated coverslips and processed for immunofluorescence staining. For our analysis, we performed only the first step of enrichment and omitted the second step of automated staining with cytokeratins, DAPI and CD45 which is used for CTC enumeration. In addition, to ensure analysis of PC CTCs among the leucocytes present in the EpCAM-enriched cell population, we stained for PSMA (prostate specific marker) and CD45 (leucocyte specific marker) and analyzed the PSMA+/CD45-cells for AR subcellular localization using multiplex confocal microscopy. Using Subsequent to attachment, cells were fixed and processed for immunofluorescence and confocal microscopy as described below. antibodies used were Alexa 488-conjugated goat anti-rabbit immunoglobulin G (IgG; 1:500), Alexa 568-conjugated goat anti-mouse IgG (1:500) and Alexa 647-conjugated goat anti-rat IgG (1:500). DNA was stained with 1μg ml
Immunofluorescence and confocal microscopy
Louis, MO). The cells were mounted using Mowiol (Calbiochem, Darmstadt, Germany) and imaged using a Zeiss LSM 5 LIVE (Thornwood, NY) confocal microscope using 63x/1.4 Plan APOCHROMAT and 100x/1.4 Plan APOCHROMAT objectives. All images were acquired and analyzed using Zeiss LSM 5 LIVE software.
Quantitation of AR subcellular localization in CTCs
CTCs were obtained by CellSearch enrichment or Ficoll separation for each patient at each time point. CTCs were imaged with a Zeiss 5 LIVE confocal microscope using a 20X objective. A single plane image of each cell was taken and analyzed using the MetaMorph imaging software 
Statistical Analysis
For CTCs isolated from the fourteen patients, we determined both the AR subcellular localization and total AR fluorescence intensity at each patient visit. AR localization was defined as follows: if greater than 50% of CTCs in a given sample have a meaningful percentage of AR in cytoplasm (>40%), we considered AR localization as cytoplasmic, otherwise, we considered response/stable disease) was included in the analysis. Fisher's exact test was used to correlate AR localization in the nucleus with the patients' clinical response to treatment assessed using PSA working group 2 criteria. Considering the longitudinal nature of the data, the association between the AR measurements and the PSA outcome was more rigorously assessed using the generalized linear mixed effects models [30] [31] [32] . Effects with p-values <0.05 was considered statistically significant.
RESULTS
Taxanes inhibit AR nuclear accumulation and signaling
Since microtubules are involved in transcription factor trafficking, we investigated the effects of taxane treatment on AR nuclear translocation in LNCaP PC cells. Cells were treated with paclitaxel (PTX) followed by the addition of the di-hydrotestosterone (DHT) analog R1881 ( Fig. 1A-C) and analyzed for evidence of PTX-induced microtubule bundling and R1881-induced AR nuclear accumulation by confocal microscopy. Interestingly, PTX induced a significant decrease in AR nuclear accumulation, at both baseline and following R1881 treatment (Fig. 1A-C) .
Quantitation of the extent of PTX-induced AR nuclear exclusion revealed a significant decrease in the percentage of cells with nuclear AR, following R1881 treatment, from 70% to <30% ( Fig.   1B ; p<0.001) and a concomitant 50% decrease in the total fluorescence intensity of nuclear AR staining ( Fig. 1C; p<0 .001). The profound cytoplasmic sequestration of AR following paclitaxel treatment implicated microtubules in the shuttling of the receptor from the cytoplasm to the nucleus. To explore the dynamics of ligand induced AR nuclear translocation, we introduced full-length GFP-AR into PC3 cells stably expressing mCherry tubulin (PC3:mCherry-tub) ( stabilized microtubules as early as 30 min post R1881 addition (p<0.01-0.001). Consistent with drug-induced AR nuclear exclusion, we also observed dose-dependent inhibition of AR transcriptional activity using a luciferase reporter assay in LNCaP cells expressing endogenous AR ( Fig. 2A) . Similarly, docetaxel (DTX) treatment inhibited ligand-induced protein expression (Fig. 2B) and secretion of prostate specific antigen (PSA; Fig. 2C ), an AR target gene used clinically to monitor biochemical disease progression in men with PC [18, 33] . Together, these results suggested that taxanes inhibit AR signaling by preventing AR nuclear accumulation.
Microtubule stabilization is a prerequisite for taxane-induced inhibition of AR signaling.
To determine whether the taxane-induced cytoplasmic sequestration of AR required prior microtubule stabilization, we utilized an isogenic model of paclitaxel-sensitive and -resistant human ovarian cancer cells, 1A9 and 1A9/PTX10, respectively, stably transfected with wild-type GFP-AR. Drug resistance in 1A9/PTX10 cells is conferred by an acquired tubulin mutation (Fβ270V) at paclitaxel's binding site [27] . Paclitaxel treatment of taxane-resistant 1A9/PTX10 cells had no effect on GFP-AR subcellular localization (Fig. 3 , right panel) (consistent with the drug's inability to stabilize microtubules), whereas DHT-induced GFP-AR nuclear accumulation was robustly inhibited by paclitaxel in parental drug-sensitive 1A9 cells (Fig. 3, left panel) .
These results demonstrated that the microtubule stabilizing activity of taxanes is required to inhibit AR translocation and downstream signaling; further implying that in cases where the drug-target interaction is impaired AR signaling will remain unaffected. To further characterize the interaction of AR with microtubules, we performed high resolution multiplex confocal microscopy in PC3 cells stably expressing AR, and observed a clear co-localization of cytoplasmic AR with intact microtubules. Following taxane treatment AR remained associated with bundled microtubules in the perinuclear region (Fig. 4A) . The tubulin-AR association was (Fig. 4B) as well as by a microtubule cosedimentation assay [14] in which AR was found preferentially associated with the microtubule polymer fraction (WP) and not the fraction containing soluble tubulin dimers (WS), lending further support to the role of microtubules as tracks for AR transport towards the nucleus (Fig. 4C) .
The microtubule-associated motor protein, dynein, mediates AR trafficking
To test this hypothesis, we investigated the involvement of the minus-end-directed microtubule-motor protein dynein, which transports cargo from the cytoplasm towards the nucleus, in AR trafficking [34] . Coimmunoprecipitation experiments revealed that AR associated with dynein, and that this interaction was increased upon ligand (R1881) induced AR nuclear translocation (Fig. 5A ). In addition, dynein co-fractionated with AR and microtubules in the cosedimentation assay (Fig. S1A) , suggesting that both dynein and AR associate preferentially with microtubule polymers. Cytoplasmic dynein, in order to drive subcellular motile functions, works in concert with several accessory proteins including dynactin, an adapter that mediates the binding of dynein to cargo structures enhancing the motor's processivity. Overexpression of the dynactin associated protein dynamitin, which disrupts the dynein-cargo interaction [28], markedly reduced AR nuclear accumulation following R1881 induction (Fig. 5B and Fig. S1B ), suggesting that following ligand binding, AR is shuttled from the cytoplasm to the nucleus via microtubules and its associated motor complexes.
AR cytoplasmic localization in CTCs correlates with clinical response to taxane chemotherapy
To assess whether taxanes inhibit AR nuclear translocation in vivo, we isolated CTCs from the blood of CRPC patients and examined PSMA (prostate specific membrane antigen) [ 
Author Manuscript Published OnlineFirst on July 28, 2011; DOI: 10.1158/0008-5472. CAN-11-1417 colocalization of AR with the microtubule cytoskeleton in patient samples (Fig. 6A) . We next investigated whether perturbation of the microtubule-AR axis in CTCs identified in CRPC patients receiving taxane chemotherapy would correlate with clinical response. As shown in Figure 6B (top panel), CTCs from a patient who was refractory to paclitaxel chemotherapy exhibited an unperturbed microtubule network with AR present in both the nucleus and cytoplasm. In contrast, in a second patient who was responding to docetaxel chemotherapy, CTCs demonstrated bundled microtubules and AR was exclusively in the cytoplasm with intense AR perinuclear staining (Fig. 6B, lower panel) . These results in 2 patients suggested that taxaneinduced microtubule bundling and AR cytoplasmic localization correlated with clinical response to chemotherapy. We therefore expanded our analysis to additional patients and used CTCs enriched from the blood of CRPC patients using EpCAM-based immunomagnetic capture (CellSearch) [29] . To identify PC CTCs among the leucocytes present in the EpCAM-enriched cell population, we stained for PSMA and CD45 (leucocyte specific marker) and analyzed the PSMA+/CD45-cells for AR subcellular localization using multiplex confocal microscopy ( Fig.   6C ). Using this methodology, we monitored longitudinally CRPC patients receiving taxanechemotherapy and investigated the association between AR's subcellular localization in CTCs and patients' clinical response to therapy. Figure 6D shows a representative example of CTCs isolated from a metastatic CRPC patient in which AR was localized in the nucleus at baseline, consistent with this patient's rising serum PSA (Fig. 6E, open symbols) , but was consistently shifted to the cytoplasm during PSA decline following chemotherapy (Figs. 6D, 6E ). In another patient (Fig. 6E, filled symbols) , AR was detected in the cytoplasm as early as 1 hour following paclitaxel administration which was followed by a significant decline in PSA. This result emphasizes fast and effective drug-target engagement in this patient's sample. Table 1) . We also examined the association between longitudinal quantitative AR measurements (either in terms of the percentage of AR in cytoplasm or the total AR intensity) and the PSA outcome using a generalized linear mixedeffects model that accounts for possible clustering of data among cells from the same sample and among samples from the same subject. This analysis revealed that the odds of responding for those with AR completely in cytoplasm was estimated to be increased by 30% compared to patients with no AR in the cytoplasm (OR=exp(0.26) =1.30, P<0.001). Similarly, using log transformed total AR intensity as the predictor, we found that increased total AR intensity is associated with decreased odds of responding. With each unit increase in the log AR intensity, the odds of responding is 24% lower (OR=exp(-0.28)=0.76, P<0.001). Interestingly, we observed Widely thought to be chemotherapy resistant [6] , androgen withdrawal was considered the only effective therapy for patients who developed metastases. Although numerous clinical studies using taxane-based regimens had demonstrated anti-tumor activity and clinical benefit in patients with CRPC, it was only in 2004 that the taxane docetaxel was proven to significantly improve overall survival [8, 9] . In 2010, the taxane cabazitaxel was shown to improve overall survival in CRPC patients who had received prior docetaxel chemotherapy [7] . These studies have proven the clinical utility of taxanes in PC.
Historically, the antitumor activity of taxanes has been attributed to inhibition of mitosis, as mitotic cell division requires the presence of highly dynamic microtubules and taxane treatment by suppressing microtubule dynamics leads to mitotic arrest in actively dividing cancer cells growing on two-dimensional tissue culture [10] . In addition to mitosis, microtubule dynamics are critically important for many interphase cellular functions such as intracellular transport and signaling, the disruption of which by taxanes has not been functionally implicated in their antitumor activity [39] . Here we provide evidence that taxanes clinical activity in PC can be attributed at least in part to the inhibition of AR activity via its effect on microtubules.
Inhibition of AR signaling as effective therapy in the castrate state has similarly been observed with agents designed to specifically target the AR axis, including the androgen synthesis inhibitor abiraterone and the novel AR antagonist MDV3100 [5] . The observation that docetaxel may also act by inhibiting AR through microtubule stabilization may explain why taxanes are the only class of active chemotherapy in CRPC, and conversely why other chemotherapeutic agents have been largely ineffective. CAN-11-1417 in individual patients over time. Using isolated CTCs from CRPC patients followed longitudinally over the course of taxane chemotherapy, we found a significant correlation between AR cytoplasmic localization and clinical response, suggesting that the changes in AR subcellular localization can be used as a predictive biomarker of response. We also detected a decrease in AR intensity. The correlation between the decrease in total AR intensity and clinical response to taxanes is consistent with AR transcriptional autoregulation [46] and our results showing that taxane treatment leads to AR cytoplasmic sequestration and subsequent inhibition of transcriptional activity (Fig 1) . These results showing that disruption of the microtubule-AR axis contributes to taxane anti-tumor activity also suggest that combining a taxane with other therapies targeting AR signaling at the level of ligand synthesis [47] or ligand-receptor interaction or DNA transactivation [48] may be synergistic.
Whether studying the effect of a taxane on AR localization in CTCs can be used as predictor of clinical response to therapy requires further study. To this end, we have begun a prospective clinical trial of CRPC patients receiving docetaxel chemotherapy to determine if AR localization following chemotherapy correlates with response, and whether tubulin and/or AR mutations correlate with docetaxel resistance. The ability to monitor these events in CTCs over the course of a patient's treatment will enable early therapeutic interventions and help elucidate the mechanisms of drug-resistance in CRPC patients.
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